Active Comparator Trial of Teriparatide vs Alendronate for Treating Glucocorticoid-Induced Osteoporosis: Results From the Hispanic and Non-Hispanic Cohorts
Benito R. Losada(Hospital Clínico Universitario de Caracas), Margaret R. Warner(Eli Lilly (United States)), José Zanchetta(Universidad del Salvador), Charlie C. Liu(Eli Lilly (United States)), Rachel B. Smith(Environment Agency), Antonio Nino(Eli Lilly (United States)), Cristiano A. F. Zerbini(Centro Paulista de Investigação Clinica), José Fernando Molina, Kelly Krohn(Eli Lilly (United States)), Pilar de la Peña(Universidad de Oviedo)
Cited by 20
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k